Obermatt
See Similar Stocks →

Flags

Earnings warningFinancial distress

PTC Therapeutics

NSQ:PTCT · US69366J2006
BiotechnologyMedium

360

12
EV / EBIT61
Price / Owner Earnings92
Owner Earnings Yield1
Dividend Yield1
Price/Sales48
EV / Gross Profit24
Price/Book92
Return on Capital68
Cash Return on Capital51
EBIT Margin42
Gross Profitability43
Accruals13
Owner Earnings Margin51
Sales growth7
Profit Growth83
Long-Term EPS Growth33
Owner Earnings Growth16
Reinvestment25
Price momentum62
Debt load9
Refinancing65
Debt Payback1
Liquidity56
Analyst ratings24
Opinion Changes44
Price Target Upside34
Market mood41
Value Creation0/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

PTC Therapeutics doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryBiotechnology
SizeMedium
TypePublic Company
ExchangeNASDAQGS
Founded1998
Employees1,006
Websiteptcbio.com
ISINUS69366J2006
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
GeneticsInflammationPharmacovigilanceGenetic DisorderNeurologyCentral Nervous SystemBiotechnologyHealth CareTherapeutics

Description

PTC Therapeutics, Inc. is a global biopharmaceutical company. The company's discovery, development, and commercialization of clinically differentiated medicines target children and adults living with rare disorders. It is advancing a robust and dive…

Analysis

Middle-of-the-road

PTC Therapeutics, Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is tepid and the balance sheet is stretched. The company scores 0/20 on our value-creation score: not creating value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
17
2026

All-time high

45

Mar 2026

All-time low

17

Jun 2026

Average rank

31

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
48
—
—
—
Price/Earnings
6
—
—
—
Price/Book
92
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
37
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare PTC Therapeutics with its peers
Sarepta Therapeutics
NSQ:SRPT
69
CountryUSA
IndustryBiotechnology
SizeLarge
Full Stock Analysis →
Krystal Biotech
NSQ:KRYS
96
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Karyopharm Therapeutics
NSQ:KPTI
6
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Maravai LifeSciences Holdings
NSQ:MRVI
35
CountryUSA
IndustryLife Sciences Tools & Services
SizeMedium
Full Stock Analysis →
Contineum Therapeutics
NSQ:CTNM
80
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Tarsus Pharmaceuticals
NSQ:TARS
29
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →